Dr Reddy Laboratories : Business Responsibility and Sustainability Report 2021-22

Executive6Summary -

BusinessJ ResponsibilityJ andJSustainabilityJJ Report

CORPORATE OVERVIEW

STATUTORY REPORTS

FINANCIAL STATEMENTS

This is the 'rst year in which the Company has voluntarily released its report against the new Business Responsibility & Sustainability Report guidelines. Through this report, the Company intends to communicate its vision of a purpose-driven,future-ready and sustainable roadmap and has disclosed how it manages environmental, social and governance performance.

We are driven by our purpose of 'Good Health Can't Wait'. This applies not only to an individual but also to our society and our environment.

Sustainability for us means operating in a manner that respects people, planet and purpose - helping us conserve precious resources, serve our patients, create value for stakeholders, give back to society, ful'l our potential and maintain our integrity and transparency.

For more information on our sustainability journey so far, and our refreshed sustainability goals and targets, please refer to page 16-17 of this Annual Report.

Sustainability is deeply embedded in our purpose and forms the core of our organization. Our commitment to the nine principles of National Guidelines on Responsible Business is outlined in this Report.

24

Dr. Reddy's Laboratories Limited

Annual Report 2021-22

25

Key highlights of BRSR Report

Principle 1

Conduct and govern with integrity, and in a manner that is Ethical, Transparent and Accountable

• "##% of our Key Managerial Personnel (KMPs) and 78% of our employees received periodic training on business, regulations, code of business conduct and ethics as well as economic and environmental, social and governance parameters
• No disciplinary action against Directors/KMPs/ Employees/Workers by any law enforcement agencies for charges of bribery/corruption

Principle 2

Provide goods and services in a manner that is;sustainable and safe

HH% of our global hazardous waste are sent to industries and recyclers for co-processing and recycling

CORPORATE OVERVIEW

Principle 6

Respect and make e?orts to protect and restore the environment

• "K% reduction in energy intensity from previous financial year
• "K% reduction in water intensity from previous financial year
• 8"% reduction in Scope " & 8 GHG emission intensity from previous financial year
• Fuel substitution projects implemented (Coal to Briquettes and Furnace Oil to Piped Natural Gas)

STATUTORY REPORTS

FINANCIAL STATEMENTS

Principle 7

Influencing public and regulatory policy, in a responsible and transparent manner

Associated with trade and industry chambers/ associations to foster dialogue on industry growth drivers, innovation and shaping public policy

Principle 4

Respect the interests of and be responsive to all its stakeholders

Comprehensive stakeholder engagement at frequent intervals using multiple platforms to understand their expectations, inform our strategy and communicate our progress

Principle 3

Respect and promote the well-being of all employees, including those in value chains

• "##% of our employees (permanent, workers and others) are covered under health and accident insurance.
• "##% of our employees (permanent, workers and others) are covered by maternity and paternity benefits.

• Achieved a H7."% return-to-work rate post	Principle 5
parental leave
	Respect and promote human rights
	• "##% of our employees and workers are paid
	more than the minimum wage
	• Median remuneration of employees is more than
^ Lakhs per annum

Principle 8

Promote inclusive growth and equitable development

• Y"% of input materials were sourced locally, directly from within the district and neighbouring districts
• Positively impacted Z,[K,ZZ8 individuals through CSR initiatives

Principle 9

Engage with and provide value to the consumers in a responsible manner

• No data breaches reported during the reporting period
• No major critical service disruptions

26

Dr. Reddy's Laboratories Limited

Annual Report 2021-22

27

BUSINESSLRESPONSIBILITYLANDL SUSTAINABILITYLREPORTLNBRSRO

CORPORATE OVERVIEW

STATUTORY REPORTS

FINANCIAL STATEMENTS

IV EMPLOYEES

M. DETAILS AS AT THE END OF FINANCIAL YEAR:

1. EMPLOYEES AND WORKERS 2INCLUDING DIFFERENTLY ABLED9

SR.	PARTICULARS	TOTAL	MALE		FEMALE
NO
		NUMBER	%	NUMBER	%

SECTION A G GENERAL DISCLOSURE

I DETAILS OF LISTED ENTITIES

M. CORPORATE IDENTITY NUMBER	Y.	EZMAIL
RCINS OF THE LISTED ENTITY		[e-mail]
L7^"H^TG"H7KPLC##K^#Y	[.	TELEPHONE
U. NAME OF THE LISTED ENTITY		+H"-K#-KH##8H##
Dr. Reddy's Laboratories Limited	.	WEBSITE

1. PAIDZUP CAPITAL INR 7Z8,"8H,8K^

MU. NAME AND CONTACT DETAILS RTELEPHONE, EMAIL ADDRESSS OF THE PERSON WHO MAY BE CONTACTED IN CASE OF ANY

Employees
1	Permanent	8#,"88	"Y,YH^	77.KK	8,Z8Y	"".^[
2	Other than permanent	K,777	Z,HHY	7".YY	7H"	"7.8Z
	Total	UX,_M_	UM,[^U	[.MV	V,UM	MU.[
Workers
1	Permanent	^8H	^#H	H[.88	8#	Z.Y7
2	Other than permanent*	^,8Z#	-	-	-	-
	Total	X,[X^	-	-	-	-

1. YEAR OF INCORPORATION "H7K
2. REGISTERED OFFICE ADDRESS
   7-8-ZZY, Road No. Z, Banjara Hills, Hyderabad, Telangana ^###ZK India
3. CORPORATE ADDRESS
   7-8-ZZY, Road No. Z, Banjara Hills, Hyderabad, Telangana ^###ZK India

www.drreddys.com

• FINANCIAL YEAR FOR WHICH REPORTING IS BEING DONE G
  April ", 8#8" to March Z", 8#88

M_. NAME OF THE STOCK EXCHANGERSS WHERE SHARES ARE LISTED G

BSE, NSE, NYSE and NSE-IFSC

QUERIES ON THE BRSR REPORT

Mr. Erez Israeli,

Chief Executive Oecer E-mail id: [e-mail] Contact No: +H"-#K#-KH## 8H##

MV. REPORTING BOUNDARY

The disclosure under this BRSR is on standalone basis unless otherwise stated

*Gender split not available. We are in process of establishing a mechanism to record the details.

1. DIFFERENTLY ABLED EMPLOYEES AND WORKERS

SR.			MALE		FEMALE
PARTICULARS	TOTAL
NO	NUMBER	%	NUMBER	%
Di?erently abled Employees
1	Permanent	[#	K7	7#	"8	8#
2	Other than permanent	-			-
	Total	Y_		Not available
Di?erently abled Workers

1. PRODUCTS AND SERVICES

14. DETAILS OF BUSINESS ACTIVITIES 2ACCOUNTING FOR 90% OF THE TURNOVER9

SR.	DESCRIPTION OF MAIN	DESCRIPTION OF BUSINESS ACTIVITY	% OF TURNOVER OF
NO	ACTIVITY	THE ENTITY
1	Pharmaceuticals	Development, manufacturing & sale of pharmaceutical products, and services	"##%

15. PRODUCTS/ SERVICES SOLD BY THE ENTITY 2ACCOUNTING FOR 90% OF THE ENTITY'S TURNOVER9

SR.	PRODUCTS	NIC CODE	% OF TOTAL TURNOVER
NO	CONTRIBUTED
1	Development, manufacturing & sale of Generic Formulations including Biosimilars	8"##H	7"
2	Development, manufacturing & sale of Active Pharmaceutical Ingredients & Custom	8"##H	"Y
	Pharmaceutical Services

1. OPERATIONS

16. NUMBER OF LOCATIONS WHERE PLANTS AND/ OR OPERATIONS/ OFFICES OF THE ENTITY ARE SITUATED

	NUMBER OF PLANTS	NUMBER OF
LOCATION	2INCLUDING R&D SITES/	TOTAL
OFFICES
	OPERATIONS9

National	8Z	7	Z"
International	H	^#	^H

M[. MARKETS SERVED BY THE ENTITY

A. NUMBER OF LOCATIONS

LOCATIONS	NUMBERS
National (Number of States)	Pan-India
International (Number of Countries)	66

1. Contribution of exports as a percentage of the total turnover of the entity
   Out of the total turnover of INR "Z,77[ crore (excluding service income), the turnover of the products sold in India is INR K,8YH crore (Z"%) and that of other countries is INR H,[#Y crore ([H%).
2. A brief on types of customers
   Our customers include wholesalers, distributors, pharmacy chains and hospitals, government institutions and other pharmaceutical companies.

1	Permanent
2	Other than permanent	Not available
	Total

19. PARTICIPATION/ INCLUSION/ REPRESENTATION OF WOMEN

PARTICULARS	TOTAL	NUMBER OF	%
FEMALES	OF FEMALES
Board of Directors	""	Z	8Y
Key Managerial Personnel (KMPs)	Z	#	#

20. TURNOVER RATE FOR PERMANENT EMPLOYEES AND WORKERS

PARTICULARS		FY U_UMZUU			FY YZYZ[Y*			FY YZ^[YZ*
	MALE	FEMALE	TOTAL	MALE	FEMALE	TOTAL	MALE	FEMALE	TOTAL
Permanent Employees	"Y%	"H.Z%	"Y%	-	-	"Y.^%	-	-	"7."%
Permanent Workers					Not available

*Gender wise splits are not available.

V G HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES RINCLUDING JOINT VENTURESS

UM. NAMES OF HOLDING/ SUBSIDIARY/ ASSOCIATE COMPANIES/ JOINT VENTURES

The details of holding/ subsidiary/ associate companies/ joint ventures are given in Form AOC-", as Annexure-I to the Board's Report forming part of the Annual Report 8#88.

Do the entities indicated in above table, participate in the business responsibility initiatives of the listed entity? (Yes/No)

The major subsidiary companies are closely integrated with our corporate business responsibility initiatives.

VI G CSR DETAILS

1. WHETHER CSR IS APPLICABLE AS PER SECTION MVX OF THE COMPANIES ACT, U_MV: Yes
2. 1. Turnover - INR "K,K#^ Crore
   2. Net Worth - INR "7,ZZ[ Crore

28

Dr. Reddy's Laboratories Limited

Annual Report 2021-22

29

Our Co-Chairman& Managing Director drives the sustainability/ ESG agenda in the Company, pushing for strong action and has the ultimate responsibility to approve Dr. Reddy's ESG strategy and goals. He reports to the Board and updates them on the financial implications of climate risks and opportunities as part of the business performance review and ESG update to the Board.

VII G TRANSPARENCY AND DISCLOSURES COMPLIANCES

COMPLAINTS/ GRIEVANCES ON ANY OF THE PRINCIPLES 2PRINCIPLES 1 TO 99 UNDER THE NATIONAL GUIDELINES ON RESPONSIBLE

23. BUSINESS CONDUCT

	GRIEVANCE		FY U_UMZUU			FY YZYZ[Y
	REDRESSAL
	MECHANISM		NUMBER OF			NUMBER OF
STAKEHOLDER GROUP	IN PLACE 2YES/	NUMBER OF	COMPLAINTS		NUMBER OF	COMPLAINTS
FROM WHOM COMPLAINT	NO9 2IF YES,	COMPLAINTS	PENDING	REMARKS	COMPLAINTS	PENDING	REMARKS
IS RECEIVED	THEN PROVIDE	FILED DURING	RESOLUTION	FILED DURING	RESOLUTION
	WEB[LINK FOR	THE YEAR	AT CLOSE OF		THE YEAR	AT CLOSE OF
	GRIEVANCE		THE YEAR			THE YEAR
	REDRESS POLICY9
Communities	Yes*	#	#		#	#
Investors other than	Yes*	#	#		#	#
Shareholders
Shareholders	Yes*	[	#		7	#
Employees and Workers	Yes*	8"Z	88		"8[	"7
Customers	Yes*	"K	Z		[	"
Value Chain Partners	Yes*	8	#		Y	#
Others**	Yes*	Y#	Y		87	K

• Some of the policies guiding the Company's conduct with all its stakeholders, including grievance mechanisms are placed on the Company's website. The link is: https://www.drreddys.com/investor#governance. In addition, there are internal policies placed on the intranet platform of the Company. The number of complaints are not comparable with that of the previous year. FYGHGI, when owing to the pandemic, the oJces were intermittently closed. Complaints pending as at the financial year end, but subsequently resolved.

**For FYGHGI-GG, out of NH, OP are anonymous and P are from identified unrelated parties. For FYGHGH-GI, out of GQ, GO are anonymous, I is from identified unrelated parties and I is from identified relative of an employee.

UW. OVERVIEW OF THE ENTITY'S MATERIAL RESPONSIBLE BUSINESS CONDUCT ISSUES

The Company's Executive Risk Management Committee operates under the Company's Risk Management Policy. Its focus is on risks associated with the Company's business and compliance matters. The Committee periodically reviews matters pertaining to risk management. Additionally, the Enterprise-wide Risk Management (ERM) function helps management and the Board to prioritize, review and measure business risks against a pre-determined risk appetite, and their suitable response, depending on whether such risks are internal, strategic or external (including ESG and Cyber security risks). There is a Risk Management Committee of the Board of Directors which is regularly appraised of the various Company's Risks.

Refer page nos. KH and ^# of the 8#8" Sustainability Report at the link https://www.drreddys.com/cms/cms/sites/default/ files/GHGG-HR/sustainability-report-fy-GHGH-GI.pdf, for more information on the Company's emerging climate related risks.

SECTION B G MANAGEMENT AND PROCESS DISCLOSURES

DISCLOSURE QUESTION

P b

P b Y

P b c

P b d

P b e

P b f

P b g

P b h

P b ^

Policy and Management Process

1. A. Whether your entity's policy/ policies

	cover each principle and its core	Yes	Yes	Yes	Yes	Note "	Yes	Note 8	Yes	Yes
	elements of the NGRBCs. (Yes/No)
1.	B. Has the policy been approved by the	The statutory policies are approved by the Board or Board Committees, as applicable. Other
	Board? (Yes/No)	applicable policies are either approved by the Board or by the appropriate authority.
1.	C. Web Link of the Policies, if available					Note 3
2.	Whether the entity has translated the policy	Yes. The Company's Code of Business Conduct and Ethics (COBE) imbibes the above-mentioned
	into procedures. (Yes/No)	principles and the Company expects its stakeholders to adhere to the same in all their dealings.
3.	Do the enlisted policies extend to your value Yes. The Company's COBE imbibes the above-mentioned principles and the Company expects its
	chain partners? (Yes/No)	stakeholders to adhere to these in their dealings.
4.	Name of the national and international	SA8000	ISO	ISO	-	SA8000	-	-	As per the	-
	codes/certifications/labels/ standards (e.g.		14001	45001					CSR Rules
	Forest Stewardship Council, Fairtrade,			SA8000					prescribed
	Rainforest Alliance, Trustea) standards (e.g.								under the
	SA 8000, OHSAS, ISO, BIS) adopted by your								Companies
	entity and mapped to each principle								Act, 2013
5.	Specific commitments, goals and targets set					Note K
	by the entity with defined timelines, if any
6.	Performance of the entity against the
	specific commitments, goals and targets					Note ^
	along-with reasons in case the same are not

met

		CORPORATE OVERVIEW	STATUTORY REPORTS	FINANCIAL STATEMENTS
DISCLOSURE QUESTION	P b	P b Y	P b c	P b d	P b e	P b f	P b g	P b h	P b ^
Governance, Leadership and Oversight
7.	Statement by Director responsible for the	At Dr. Reddy's, we are committed to make business truly sustainable and responsible . The Board
	business responsibility report, highlighting	has made a Board level Committee responsible for sustainability and ESG road-map and review of
	ESG related challenges, targets and	the implementation. 2020 and 2021 will go down in history as a period of unprecedented strain,
	achievements (listed entity has flexibility	disruption, and challenges. However, it will also be remembered as the time humanity united
	regarding the placement of this disclosure)	and solved the pandemic induced health, social, and economic crises. Covid-19 highlighted the
		devastating impact of systemic inequalities and disparities and taught humanity some crucial
		lessons. It made us deeply examine our practices, mindsets, and the urgent need to operate and
		grow sustainably.
		We see the coming year as a significant opportunity to integrate ESG into our organizational
		culture, using it to drive our daily decisions while we strive to meet the needs of patients and
		create a net positive impact on our ecosystem. Dr. Reddy's is committed to deliver its ESG agenda
		by generating value for its stakeholders, driving sustainability with technological progress and
		manufacturing excellence. Our exorts remain focused on expanding access and axordability to
		safe, exective and high-quality medicines that the world can count on, because, - Good Health
		Can't Wait.
7.	Details of the highest authority responsible	Mr. Erez Israeli
	for implementation and oversight of the	Chief Executive Oecer
	Business Responsibility policy (ies)	Tel: [phone]
		E-mail ID: [e-mail]

9. Does the entity have a specified Committee Mr. G V Prasad, Co-Chairman & Managing Director

of the Board/ Director responsible for decision making on sustainability related issues? (Yes/ No). If yes, provide details

Note M: The Company complies with all the statutory requirements. All the contracts and standing orders include relevant aspects of human rights.

Note U: The Company works closely with various trade and industry associations. This includes industry representations to the government and/ or regulators. The Company performs the function of policy advocacy in a transparent and responsible manner while engaging with all the authorities and considers the Company's interest as well as the larger national interest. The Company believes that policy advocacy must preserve and expand public good and thus, it does not advocate any policy change to benefit itself alone or a select few.

Note V: https://www.drreddys.com/media/UQVONO/cobe-booklet-vRH.pdfhttps://www.drreddys.com/media/QQQIRN/she-policy-document-GR-HN-GHGH.pdfhttps://www.drreddys.com/media/QUUPVO/human-rights-policy_HIHUGHGH.pdfhttps://www.drreddys.com/media/UUVGGP/csr-policy.pdfhttps://www.drreddys.com/cms/cms/sites/default/files/static/supplier-code-of-conduct-new.pdf

Note W: We strengthened our commitment to sustainability and announced new environmental, social, and governance (ESG) goals for GHVH to make more meaningful impact through our sustainable development strategy.

A. Being committed to environmental stewardship: Reducing carbon emissions

• IHH% renewable power (REIHH) by GHVH; • Carbon neutral in direct operations (Scope I and G emissions) by GHVH; • IG.P% reduction in our indirect carbon emissions (Scope V) by GHVH

Water positivity

1. • Water positive by GHGP
2. Making our products accessible and a=ordable for patients Access: • Serve I.P billion+ patients by GHVH
   A=ordability : • GP% of our new launches to be first to market by GHGN
   Innovation : • V innovative products improving the standard of treatment every year
3. Contributing to a fairer and more socially inclusive world Equity, diversity and inclusion
4. • At least VP% women in senior leadership (VX from current) by GHVH; • Gender parity by GHVP; • V% of our workforce to be Persons with Disability (PwD) by GHVH; • Ensure IHH% living wages for our extended workforce by GHGP
5. Enhancing trust with our stakeholders
   Compliance, Ethics, and Corporate governance: • Meet the highest standards on compliance and ethics backed by robust corporate governance
   Disclosures and reporting
6. • Enhance our disclosures to reach top quartile by GHGP

Suppliers

• IHH% of our strategic suppliers to be compliant with our internal ESG framework by GHVH

Note X: Some of our ESG progress against goals in FY IJII is provided below:

• GO% of our total power is through renewable sources; • We have reduced II% of our absolute scope I & G emissions, and H.V% of scope V emissions since FY GHGI; • We are NQ% water neutral

For more details on our ESG goals and journey, refer to page nos. IO-IN of the Annual Report FYGHGG.

30

Dr. Reddy's Laboratories Limited

Annual Report 2021-22

31

10. DETAILS OF REVIEW OF NGRBCS BY THE COMPANY

SUBJECT FOR REVIEW	REVIEW OF PRINCIPLES UNDERTAKEN BY AND FREQUENCY
Performance against above policies and follow up	As a practice, BR policies of the Company are reviewed periodically or on a need
action	basis by department heads, business heads and Executive Directors. During such
	assessment, eecacy of the policies are reviewed and necessary changes to policies
	and procedures are implemented. The Board also reviews the Business Responsibility
	Report on an annual basis.

Compliance with statutory requirements of relevance to The Company is in compliance with the extant regulations, as applicable. the principles and rectification of any non-compliances

• Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide name of the agency
  The processes and compliances are subject to scrutiny by internal auditors and status of compliances are updated to the Board. From best practices as well as from a risk perspective, policies are periodically evaluated and updated by various department heads, business heads and approved by the management and/ or by the Board. Some of the policies of the Company are evaluated by KPMG and DNV Business Assurance India Private Limited (DNV). An internal assessment of the workings of the BR policies has been done.

"8. If answer to question (M) above is "No" i.e. not all Principles are covered by a policy, reasons to be stated: Not applicable

SECTION C G PRINCIPLE WISE PERFORMANCE DISCLOSURE

PRINCIPLE M: BUSINESSES SHOULD CONDUCT AND GOVERN THEMSELVES WITH INTEGRITY, AND IN A MANNER THAT IS ETHICAL, TRANSPARENT AND ACCOUNTABLE

	CORPORATE OVERVIEW	STATUTORY REPORTS	FINANCIAL STATEMENTS
NON[MONETARY
NGRBC	NAME OF THE REGULATORY/ ENFORCEMENT	AMOUNT 2INR9	HAS AN APPEAL BEEN
PRINCIPLE	AGENCIES/ JUDICIAL INSTITUTES		BRIEF OF THE CASE	PREFERRED 2YES/NO9?

Imprisonment

Nil

Punishment

1. Of the instances disclosed in Question Y above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed
   Not applicable
2. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy
   Yes. Dr. Reddy's has an anti-bribery and anti-corruption policy. The policy has been developed in alignment with Dr. Reddy's Code of Business Conduct and Ethics (COBE), other internal policies such as Ombudsperson policy and other rules and regulations on against elements of Anti bribery and Anti-Corruption that govern the Company because of its geographical presence in multiple countries. The policy reiterates that Dr. Reddy's does not tolerate any bribery and corruption and continues to uphold the highest standards of integrity and transparency in all its interactions and routine business activities. The policy forms part of the COBE, applies to all members of the Board of Directors, full and part-time employees of the Company, its subsidiaries and aeliates. All business partners are also expected to follow the same standard of ethics when conducting business with the Company or on its behalf. (https://www.drreddys.com/investor#governance)

ESSENTIAL INDICATORS

1. PERCENTAGE COVERAGE BY TRAINING AND AWARENESS PROGRAMMES ON ANY OF THE PRINCIPLES DURING THE FINANCIAL YEAR

5.

NUMBER OF DIRECTORS/ KMPS/ EMPLOYEES/ WORKERS AGAINST WHOM DISCIPLINARY ACTION WAS TAKEN BY ANY LAW ENFORCEMENT AGENCY FOR THE CHARGES OF BRIBERY/ CORRUPTION

			% AGE OF PERSONS IN
SEGMENT	TOTAL NUMBER OF TRAINING AND	TOPICS/ PRINCIPLES COVERED	RESPECTIVE CATEGORY
AWARENESS PROGRAMMES HELD	UNDER THE TRAINING AND ITS IMPACT	COVERED BY THE AWARENESS
			PROGRAMMES
Board of Directors	Familiarisation/ awareness program for the Board of Directors/ KMPs of the Company	"##%
(BODs)/ Key	is done periodically. The topics cover business, regulations, code of business conduct
Managerial Personnel and ethics, economy and environmental, social and governance parameters. In
(KMPs)	addition, frequent updates are shared with all the Board members/ KMPs apprising
	them on developments in the Company, key regulatory changes, risks, compliances,
	and legal cases.
Employees other than The employees/ workers of the Company undergo various training programmes	7".^^%
BODs and KMPs	throughout the year. Owing to the pandemic, many trainings programs happened
	through a blended learning approach which entailed virtual classroom initiatives, along
	with dissemination of e-learning modules.
	Various trainings were undertaken during the year: Prohibition of Insider Trading,
	Prevention of Sexual Harassment at the Workplace, Information and Cyber Security
Workers	48.28%

Awareness, Code of Conduct, Know Your Customer guidelines, and a learning module on ESG. Other trainings included induction programmes for new recruits, leadership training, IT and cyber security and modules on soft skills, programmes on mental and physical well-being, among several others. Regular mailers are sent to employees on ethics, health, ESG and other relevant topics as part of the awareness programmes. The various updates are also placed at the intranet platforms of the Company.

1. Details of fines/ penalties/ punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by Directors/ KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation cZ of SEBI (Listing Obligations and Disclosure Requirements) Regulations, YZe and as disclosed on the entity's website):

MONETARY

	NGRBC	NAME OF THE REGULATORY/			HAS AN APPEAL BEEN
	ENFORCEMENT AGENCIES/	AMOUNT 2INR9	BRIEF OF THE CASE
	PRINCIPLE	PREFERRED 2YES/NO9?
	JUDICIAL INSTITUTES
Penalty/ Fine
Settlement		Nil
Compounding Fees

			FY U_UMZUU			FY YZYZ[Y
	Directors
	KMPs		Nil
	Employees
	Workers
6. DETAILS OF COMPLAINTS WITH REGARD TO CONFLICT OF INTEREST
			FY U_UMZUU			FY YZYZ[Y
		NUMBER	REMARKS		NUMBER	REMARKS
	Number of complaints received in relation to issues of conflict of
	interest of the Directors
		Nil	Not applicable		Nil	Not applicable
	Number of complaints received in relation to issues of conflict of
	interest of the KMPs

1. Details of any corrective action taken or underway on issues related to fines/ penalties/ action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest
   Not applicable

LEADERSHIP INDICATORS

1. AWARENESS PROGRAMMES CONDUCTED FOR VALUE CHAIN PARTNERS ON ANY OF THE PRINCIPLES DURING THE FINANCIAL YEAR

TOTAL NUMBER		% AGE OF VALUE CHAIN PARTNERS COVERED
OF AWARENESS	TOPICS/ PRINCIPLES COVERED UNDER THE TRAINING	2BY VALUE OF BUSINESS DONE WITH SUCH PARTNERS9
PROGRAMMES HELD		UNDER THE AWARENESS PROGRAMMES
1	Environment, Social & Governance, Supplier Code of	"[.8
	conduct, PSCI assessment checklist

1. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No) If Yes, provide details of the same.
   As part of the Governance ecosystem, the Company has adopted best practices on reviews of conflict of interest of Directors. The Director's disclosures are placed before the Board and conflict of interest, if any, is discussed and reviewed. The Board collectively is responsible for decision making on conflict of interest disclosed to the Board for any business decisions, wherein any of the Directors are interested.

32

Dr. Reddy's Laboratories Limited

Annual Report 2021-22

33